GLP-1 drugs have been studied for effects far beyond weight and blood sugar, and one of the more closely watched efforts was Novo Nordisk's attempt to test whether semaglutide could slow the progression of early Alzheimer's disease. The results, announced in late 2025, are a useful case study in how a scientifically reasonable hypothesis can still fail to pan out in a rigorous trial — and in how companies communicate that kind of result.
The Trials: EVOKE and EVOKE+
EVOKE and EVOKE+ were two large Phase 3 trials, together enrolling 3,808 adults with mild cognitive impairment or mild dementia due to Alzheimer's disease, comparing semaglutide against placebo. The rationale wasn't arbitrary: GLP-1 receptors are present in the brain, GLP-1 drugs have shown anti-inflammatory and metabolic effects in other contexts, and some earlier, smaller signals had suggested a possible neuroprotective benefit worth testing in a dedicated Alzheimer's population. Running two trials of this size, in a disease this difficult to treat, represented a substantial and genuinely uncertain bet by Novo Nordisk.
What the Topline Results Showed
Novo Nordisk announced topline results on November 24, 2025: semaglutide did not demonstrate a statistically significant reduction in Alzheimer's disease progression compared with placebo. In other words, on the measures that mattered most for the trial's primary question — whether the drug could meaningfully slow decline in cognition or function — it did not succeed. The company did report that semaglutide improved certain Alzheimer's-related biomarkers, but was clear that this biomarker movement did not translate into a clinically meaningful difference in disease progression. Novo's own head of research and development stated that the company had felt a responsibility to test semaglutide's potential despite acknowledging a low likelihood of success going in, and the company discontinued a planned one-year extension of the trials following the negative result.
Why a Negative Trial Like This Still Matters
A failed trial of this scale isn't a wasted one. Alzheimer's disease has an extraordinarily high failure rate across experimental drugs generally, and a rigorously designed, adequately powered trial that cleanly fails to show benefit is scientifically valuable: it tells other researchers that this specific approach, in this specific population, at this specific dose and duration, isn't the answer, which helps redirect effort elsewhere. The biomarker-versus-clinical-outcome gap seen in EVOKE and EVOKE+ is also a useful real-world illustration of a theme covered elsewhere on this site: a drug can move a biological marker without that movement translating into something a patient or their family would actually notice or benefit from.
What This Does and Doesn't Say About GLP-1 Drugs Generally
It would be a mistake to read EVOKE and EVOKE+ as a verdict on every proposed brain-related effect of GLP-1 drugs. The trials tested one specific drug (semaglutide), one specific formulation, in one specific population (people who already had diagnosed mild cognitive impairment or mild dementia from Alzheimer's disease) — not healthy people, and not other neurological or psychiatric questions being studied separately, such as the biological-aging research covered elsewhere on this site. A negative result in established Alzheimer's disease doesn't rule out effects in earlier prevention, in other conditions, or from other molecules in this drug class; it specifically rules out this drug, in this trial, for this purpose, at this dose and duration tested.
The Bottom Line
EVOKE and EVOKE+ are a clear example of how far a scientifically plausible hypothesis can go — through two full Phase 3 trials involving thousands of patients — and still not succeed. Semaglutide is not an approved or supported treatment for Alzheimer's disease, and nothing in these results changes that. Anyone concerned about Alzheimer's disease or cognitive decline, in themselves or a family member, should talk to a neurologist or primary care physician about currently approved options and appropriate evaluation, rather than an investigational use of a drug approved for diabetes and weight management.